Section Arrow
Quote
SCTX.NASDAQ
- Scribe Therapeutics Inc
Quotes are at least 15-min delayed:2026/11/04 14:31 EST
Regular Hours
Last
 17.05
+0.85 (+5.25%)
Day High 
17.35 
Prev. Close
16.2 
1-M High
22.0731 
Volume 
200.48K 
Bid
17.03
Ask
17.18
Day Low
16.18 
Open
16.75 
1-M Low
13.5 
Market Cap 
306.69M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 16.64 
20-SMA 18.24 
50-SMA 23.31 
52-W High 39.6 
52-W Low 13.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.84/-2.52
Enterprise Value
311.50M
Balance Sheet
Book Value Per Share
-8.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
27.41M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.235+0.5211+72.99%0.2PE
KPTIKaryopharm Therapeutics Inc.0.0851-0.0032-3.62%-- 
GERNGeron Corp1.035+0.105+11.29%-- 
INOInovio Pharmaceuticals1.655-0.005-0.30%-- 
NRIXNurix Therapeutics16.31-9.51-36.83%10.63PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.